Brickell Biotech, Inc.

3.63-0.4400-10.81%Vol 179.07K1Y Perf -86.45%
Aug 9th, 2022 16:00 DELAYED
BID3.44 ASK3.68
Open3.95 Previous Close4.07
Pre-Market- After-Market3.55
 - -  -0.08 -2.20%
Target Price
67.57 
Analyst Rating
Strong Buy 1.50
Potential %
1.76K 
Finscreener Ranking
 —    -
Insiders Trans % 3/6/12 mo.
-/-/- 
Value Ranking
★★★     51.16
Insiders Value % 3/6/12 mo.
-/-/- 
Growth Ranking
★★+     49.04
Insiders Shares Cnt. % 3/6/12 mo.
-/-/- 
Income Ranking
 —    -
Price Range Ratio 52W %
2.18 
Earnings Rating
Market Cap9.63M 
Earnings Date
11th Aug 2022
Alpha-0.06 Standard Deviation0.22
Beta0.23 

Today's Price Range

3.473.95

52W Range

2.8837.35

5 Year PE Ratio Range

-1.80-1.60

Summary:

Buy

Technical Indicators: Buy
Moving Averages: Buy
Performance
1 Week
29.21%
1 Month
5.99%
3 Months
-56.93%
6 Months
-63.20%
1 Year
-86.45%
3 Years
-98.39%
5 Years
-99.47%
10 Years
-99.64%

TickerPriceChg.Chg.%
BBI3.63-0.4400-10.81
AAPL164.920.05000.03
GOOG117.50-0.6400-0.54
MSFT282.301.98000.71
XOM90.591.64001.84
WFC43.400.21000.49
JNJ170.18-0.0200-0.01
FB196.640.99000.51
GE74.93-0.2500-0.33
JPM115.381.03000.90
 
ProfitabilityValueIndustryS&P 500US Markets
-
-8 317.30
-8 311.50
-1 675.80
-
RevenueValueIndustryS&P 500US Markets
328.00K
0.12
-25.98
-47.50
Earnings HistoryEstimateReportedSurprise %
Q01 2022-2.70-3.60-33.33
Q04 2021-4.05-2.7033.33
Q03 2021-4.95-7.21-45.66
Q02 2021-4.95-7.21-45.66
Q01 2021-5.41-6.76-24.95
Q04 2020-0.08-0.15-87.50
Q03 2020-0.17-0.1511.76
Q02 2020--0.43-
Earnings Per EndEstimateRevision %Trend
----
----
----
----
Next Report Date11th Aug 2022
Estimated EPS Next Report-1.48
Estimates Count2
EPS Growth Next 5 Years %-
Volume Overview
Volume179.07K
Shares Outstanding2.65K
Shares Float2.60M
Trades Count1.62K
Dollar Volume654.51K
Avg. Volume2.15M
Avg. Weekly Volume681.47K
Avg. Monthly Volume341.05K
Avg. Quarterly Volume5.43M

Brickell Biotech, Inc. (NASDAQ: BBI) stock closed at 4.07 per share at the end of the most recent trading day (a 7.96% change compared to the prior day closing price) with a volume of 236.44K shares and market capitalization of 9.63M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 16 people. Brickell Biotech, Inc. CEO is Robert Busard Brown.

The one-year performance of Brickell Biotech, Inc. stock is -86.45%, while year-to-date (YTD) performance is -60.49%. BBI stock has a five-year performance of -99.47%. Its 52-week range is between 2.88 and 37.35, which gives BBI stock a 52-week price range ratio of 2.18%

Brickell Biotech, Inc. currently has a PE ratio of -0.20, a price-to-book (PB) ratio of 0.54, a price-to-sale (PS) ratio of 24.60, a price to cashflow ratio of 82.40, a PEG ratio of 2.32, a ROA of -138.77%, a ROC of -175.48% and a ROE of -183.06%. The company’s profit margin is -%, its EBITDA margin is -8 311.50%, and its revenue ttm is $328.00 Thousand , which makes it $0.12 revenue per share.

Of the last four earnings reports from Brickell Biotech, Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-1.48 for the next earnings report. Brickell Biotech, Inc.’s next earnings report date is 11th Aug 2022.

The consensus rating of Wall Street analysts for Brickell Biotech, Inc. is Strong Buy (1.5), with a target price of $67.57, which is +1 761.43% compared to the current price. The earnings rating for Brickell Biotech, Inc. stock is (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Brickell Biotech, Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Brickell Biotech, Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 25.37, ATR14 : 0.42, CCI20 : 144.70, Chaikin Money Flow : 0.05, MACD : 0.54, Money Flow Index : 61.94, ROC : 32.57, RSI : 66.11, STOCH (14,3) : 67.61, STOCH RSI : 0.64, UO : 58.87, Williams %R : -32.39), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Brickell Biotech, Inc. in the last 12-months were:

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
3 (75.00 %)
3 (75.00 %)
3 (100.00 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
1 (25.00 %)
1 (25.00 %)
0 (0.00 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Summary RatingStrong Buy
1.50
Strong Buy
1.50
Strong Buy
1.00

Brickell Biotech, Inc.

Brickell Biotech Inc is a United States-based clinical-stage pharmaceutical company focused on developing therapeutics for the treatment of skin diseases. Its pipeline consists of therapeutics for Hyperhidrosis, Cutaneous T-cell lymphoma, Psoriasis, and Other prevalent severe skin diseases. The company's pipeline products include Sofpironium Bromide, BBI-3000, and BBI-6000 among others.

CEO: Robert Busard Brown

Telephone: +1 720 505-4755

Address: 5777 Central Avenue, Boulder 80301, CO, US

Number of employees: 16

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

64%36%

Bearish Bullish

68%32%

Bearish Bullish

66%34%


News

Stocktwits